The chimeric fusion oncogene early B-cell factor 1-platelet-derived growth factor receptor-β (EBF1-PDGFRB) is a recurrent lesion observed in Philadelphia-like B-acute lymphoblastic leukemia (B-ALL) and is associated with particularly poor prognosis. While it is understood that this fusion activates tyrosine kinase signaling, the mechanisms of transformation and importance of perturbation of EBF1 activity remain unknown. EBF1 is a nuclear transcription factor required for normal B-lineage specification, commitment and development. Conversely, PDGFRB is a receptor tyrosine kinase that is normally repressed in lymphocytes, yet PDGFRB remains a common fusion partner in leukemias. Here, we demonstrate that the EBF1-PDGFRB fusion results in loss of EBF1 function, multimerization and autophosphorylation of the fusion protein, activation of signal transducer and activator of transcription 5 (STAT5) signaling and gain of interleukin-7 (IL-7)-independent cell proliferation. Deregulation and loss of EBF1 function is critically dependent on the nuclear export activity of the transmembrane (TM) domain of PDGFRB. Deletion of the TM domain partially rescues EBF1 function and restores IL-7 dependence, without requiring kinase inhibition. Moreover, we demonstrate that EBF1-PDGFRB synergizes with loss of IKAROS function in a fully penetrant B-ALL in vivo. Thus, we establish that EBF1-PDGFRB is sufficient to drive leukemogenesis through TM-dependent loss of transcription factor function, increased proliferation and synergy with additional genetic insults including loss of IKAROS function.
INTRODUCTION
Notwithstanding a 5-year event-free survival rate surpassing 90%, acute lymphoblastic leukemia (ALL) remains a leading cause of cancer-related death for individuals under the age of 40 years. 1 Hallmarks of leukemic cells include the inability to differentiate into mature lymphocytes and unregulated cellular proliferation. 2 Ph-like (Philadelphia-like; BCR-ABL1-like) ALL is a high-risk subtype of B-cell precursor ALL defined by a gene expression profile similar to Ph + ALL. 3 Characteristically, Ph-like ALL has a diverse range of chromosomal rearrangements, mutations and DNA copy number alterations that deregulate cytokine receptor and tyrosine kinase (TK) signaling. 4 Chromosomal rearrangements in Ph-like ALL commonly result in fusions between lymphoid transcription factor and TK genes. One such fusion, early B-cell factor 1-platelet-derived growth factor receptor-β (EBF1-PDGFRB), arises from reciprocal translocation or interstitial deletion events between EBF1 exon 15 to PDGFRB exon 11 located at 5q33 ( Figure 1a ). 3, 5 EBF1 is the most common fusion partner with PDGFRB observed in Ph-like ALL. Like other PDGFRB fusions, it retains both the transmembrane (TM) and TK domains ( Supplementary Figure 1 ). [6] [7] [8] EBF1-PDGFRB occurs in ∼ 8% of Ph-like patients, is enriched in~30% patients with other B-ALL subtypes who experience induction failure and is associated with higher relapse rates. 5, 9 Patients harboring the EBF1-PDGFRB fusion frequently have additional genomic lesions resulting in the loss or competitive inhibition of essential B-lymphoid transcription factor genes including IKZF1 (IKAROS), loss of the non-rearranged allele of EBF1 and/or PAX5 and deletion of CDKN2A/B (encoding the cell cycle regulators and tumor suppressors ARF and INK4A/B). EBF1-PDGFRB results in cytokine-independent proliferation of non-ALL cell lines and human EBF1-PDGFRB leukemic cells are sensitive to tyrosine kinase inhibitors (TKIs). 3 The transcription factor EBF1 is essential for normal B-lymphocyte specification, commitment and differentiation. [10] [11] [12] [13] Loss of EBF1 results in developmental arrest at the common lymphoid progenitor stage. 13, 14 In mice, Ebf1 haploinsufficiency results in inappropriate expression of non-B-lineage genes and leukemogenesis when paired with constitutively active STAT5. [15] [16] [17] Changes in EBF1-dependent transcription have been documented in human ALL blast cells harboring mono-or biallelic EBF1 deletions. 18 Additionally, EBF1 is mutated or deleted in ∼ 8% of primary B-ALL patients and ∼ 25% of relapsed patients, suggesting it functions as a tumor suppressor. 18, 19 While it is known that chimeric fusion proteins often drive constitutive kinase signaling in leukemic cells, few data exist revealing how these proteins perturb lymphoid development and contribute to oncogenesis. Mechanistically, it is unclear whether rearrangement of PDGFRB to EBF1 is necessary for PDGFRB activation, or whether the fusion results in loss of EBF1 function. Moreover, it unknown whether EBF1-PDGFRB promotes oncogenesis by other mechanisms in addition to its unregulated TK activity, or how multiple lesions cooperate with EBF1-PDGFRB to promote leukemogenesis in Ph-like B-ALL. 3 Here, we report that EBF1-PDGFRB drives leukemogenesis through TM-dependent cytoplasmic mislocalization, which prevents EBF1 from activating transcription. Additionally, we use the first genetically faithful Ph-like B-ALL mouse model to quantify the synergism between EBF1-PDGFRB and dominant-negative IKAROS (IK6), which promote leukemogenesis in combination with Arf deletion in vivo.
MATERIALS AND METHODS

Identification of human PDGFRB fusion genes, cloning and transduction
PDGFRB fusions were identified from RNA-sequencing and reverse transcription-PCR (RT-PCR) of ALL cohorts with Ph-like ALL, with the exception of TNIP1ex17-PDGFRB, which was identified from RNA-sequencing of AML cases as described previously. 3, 20 All PDGFRB fusions were amplified from leukemic cell cDNA, cloned into Zero Blunt TOPO vector (Thermo Fisher Scientific, Waltham, MA, USA), and then subcloned into the MSCV-IRES-GFP (MIG) or MSCV-IRES-mCFP (expressing mCherry Fluorescent Protein) retroviral vectors. Retroviral supernatants produced using 293 T or Phoenix packaging cell lines were used to infect murine Ebf1 −/− fetal liver progenitors, Ba/F3 and primary Arf −/− pre-B cells as described. 21 Cell culture conditions and generation of epitope-and GFPtagged deletion/mutation constructs are detailed in Supplementary Methods.
Quantitative RT-PCR
Isolation of RNA and RT-PCR analysis from retrovirus-infected cells was described previously. 15 Primers are listed in Supplementary Table 1 . 
Fluorescence microscopy
Detailed methods for the infection and sorting of Ebf1 −/− cells, plasmacytomas and Ba/F3 cells, and analysis using confocal fluorescence microscopy are provided in Supplementary Methods.
Immunoblotting and co-immunoprecipitation
Preparation of whole-cell extracts and co-immunoprecipitation of proteins are available in Supplementary Methods.
Clonogenic assays, fluorescence-activated cell sorting/ immunophenotyping and phosphoflow
All mice experiments were reviewed and approved by the St Jude Children's Research Hospital Institutional Animal Care and Use Committee. Culture conditions, staining and analysis of cells are described in Supplementary Methods.
In vivo leukemogenesis
Generation of retrovirally transduced cells, injection into mice and subsequent analysis are described in detail in Supplementary Methods.
In vitro drug sensitivity assays TKI sensitivity was assessed using the CellTiter-Blue Cell Viability Assay (Promega, Madison, WI, USA) as per the manufacturer's instructions. Halfmaximal inhibitory concentration was determined using nonlinear regression (GraphPad Prism, La Jolla, CA, USA). Each experiment was performed three times.
Statistical analyses
Data analyses were performed using GraphPad Prism Version 6.0 (GraphPad). For quantitative RT-PCR, P-values were obtained using a two-way analysis of variance comparing column means of log-transformed values (Y = Log(Y)) with Tukey's correction for multiple comparisons. For Ebf1 − / − cell counts in proliferation assays, a two-way repeated measures analysis of variance using Tukey's correction for multiple comparisons was used to compare means across continuous time points. All P-values are described in figures. All data are presented as mean ± s.d. For Kaplan-Meier curves, significance was determined using analysis of variance test or Mantle-Cox log rank. P-values o 0.05 were considered significant.
RESULTS
The fusion oncoprotein EBF1-PDGFRB lacks EBF1 function
To determine whether EBF1-PDGFRB can activate EBF1 gene targets, we generated FLAG-tagged versions of human EBF1, PDGFRB, EBF1-PDGFRB or kinase-inactive mutant EBF1-PDGFRB (K634R), 22 each with an IRES-driven GFP marker for fluorescenceactivated cell sorting purification ( Figure 1 and Supplementary  Figures 2 and 3 ). Because it was recently reported that removal of the TM domain from a related fusion (TEL-PDGFRB) reduced its ability to impart interleukin-3 (IL-3) independence to Ba/F3 cells, 23 we also tested EBF1-PDGFRB(ΔTM) lacking the 24-residue TM domain, and EBF1-TM, which fuses the TM domain (plus 22 surrounding juxtamembrane residues) to EBF1 residues 1-583 ( Supplementary Figures 2 and 3 ). Using retroviruses, we expressed EBF1 and EBF1-PDGFRB proteins in mouse fetal-liver-derived Ebf1 − / − B progenitor cells cultured with stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (FLT3L) and IL-7. 24 On day 3 postinfection, we purified GFP + cells and quantitated expression of archetypal EBF1 target genes using quantitative RT-PCR. As expected, wild-type (WT) EBF1activated transcription of all B-cell-specific genes robustly (by as much as 1000-fold for Igll1 and Vpreb1) relative to 'empty' MIG ( Figure 1b ; P o 0.0001). EBF1-mediated gene activation was unaffected by the addition of the TKI imatinib mesylate (Gleevec, STI-571). Unlike EBF1, EBF1-PDGFRB failed to activate five of the six target genes significantly. Igll1 was activated weakly (2-3-fold), but significantly (P o 0.03). Similarly weak activation of Pax5 by EBF1-PDGFRB was observed, but significance was only achieved in the presence of imatinib. Kinase-inactive mutant EBF1-PDGFRB(K634R) produced significant (P = 0.002 and P o 0.0001), albeit modest (2-3-fold), activation of Igll1 and Cd79b, respectively, but in considerably smaller amounts relative to the large increases generated by WT EBF1.
We next examined consequences of deletion of the TM domain on transcriptional activation of EBF1 targets. Surprisingly, EBF1-PDGFRB(ΔTM) significantly activated five of the six EBF1 target genes examined (Figure 1b ; P o0.0001, compared with MIG), while also repressing non-B-lineage genes, such as CD244 ( Supplementary Figure 4) . Moreover, EBF1-PDGFRB(ΔTM) significantly activated EBF1 targets when compared with EBF1-PDGFRB or EBF1-PDGFRB(K634R). Interestingly, Asb2 was the only EBF1 target not activated significantly by EBF1-PDGFRB(ΔTM); however, it was activated~2-3-fold by EBF1-PDGFRB(K634R) relative to EBF1-PDGFRB (P o0.001) or EBF1-PDGFRB(ΔTM). The lack of activation by EBF1-PDGFRB(ΔTM) is likely due to the dependence of Asb2 transcription on the C-terminal activation domain of EBF1, which may be functionally impaired by its fusion to the TK domain of PDGFRB. 25 Thus, the oncoprotein EBF1-PDGFRB lacks normal EBF1 function, which can be rescued to a far greater degree by TM deletion than by inhibition of kinase activity using imatinib or inactivation of the kinase domain by mutation. Contrary to TM deletion, fusion of the TM domain to EBF1 (EBF1-TM) reduced the ability of EBF1 ability to activate five of the gene targets examined (Pax5 is an exception, but overall activation of this gene is weak compared with other genes) when compared with WT EBF1.
The TM domain drives subcellular mislocalization of EBF1-PDGFRB To determine whether loss of EBF1 function is due to its subcellular mislocalization, we fused EBF1 and EBF1-PDGFRB to enhanced GFP ( Supplementary Figures 2 and 3b ), which did not alter the function ( Supplementary Figures 5a and b ). We then imaged live Ebf1 −/− cells coinfected to express GFP-tagged proteins as well as untethered mCFP, which served as an internal control. When untethered, GFP and mCFP each localized diffusely throughout both the nuclei and cytoplasm (Figure 2a ). As expected, EBF1-GFP localized solely within the nuclei (Figure 2b) . Surprisingly, WT PDGFRB-GFP localized into cytoplasmic aggregates ( Figure 2c ) and was not detected on the surface of Ebf1 −/− cells by flow cytometry ( Supplementary Figure 5c ). As a control, retrovirally expressed PDGFRB-GFP was displayed on the surface of plasmacytoma cells ( Supplementary Figures 5b and d) ; therefore, the inability of Ebf1 − / − progenitors to display this receptor on the cell surface is similar to normal pre-pro-B cells, which do not display surface PDGFRB (SJW, data not shown). We conclude that normal pre-pro-B cells and Ebf1 −/− progenitors may lack a protein(s) necessary for display of surface PDGFRB.
Unlike EBF1 and PDGFRB, EBF1-PDGFRB localized diffusely throughout the cytoplasm and was virtually undetectable in the nuclei (Figure 2d ). Cytoplasmic localization using direct immunostaining was also observed in Ba/F3 cells expressing EBF1-PDGFRB and other PDGFRB fusions ( Supplementary Figure 6a ). Ba/F3 subcellular fractionation revealed that PDGFRB fusion proteins were detected only in the total membrane-bound fraction and not in the nuclear or free cytosolic compartments ( Supplementary Figure 6b ). This cytoplasmic and membrane-associated localization explains the greatly reduced ability of EBF1-PDGFRB to activate EBF1 gene targets. Importantly, inactivation of the kinase domain by imatinib or (K634R) mutation failed to relocate EBF1-PDGFRB into the nuclei (Figure 2e and Supplementary Figures 7d and e ).
Examination of the TM domain sequence using the prediction server NetNES1.1 suggested a role as a nuclear export signal (NES) peptide. 26 In support of this, we discovered that removing the TM domain completely relocalized EBF1-PDGFRB from the cytoplasm into the nuclei ( To determine whether EBF1 is necessary for the cytoplasmic localization of EBF1-PDGFRB, we generated PDGFRB(528-1106) consisting of only PDGFRB-derived fusion protein sequences ( Supplementary Figures 2 and 3b ). Similar to full-length WT PDGFRB, PDGFRB(528-1106) formed cytoplasmic puncti ( Supplementary Figure 8b) , which were also observed using imatinib-treated PDGFRB(528-1106) (data not shown) or PDGFRB (528-1106)(K634R) ( Supplementary Figure 8c ). Unlike EBF1-PDGFRB(ΔTM), PDGFRB(528-1106)(ΔTM) and PDGFRB(528-1106) (ΔTM K634R) fragments did not relocate into the nuclei, but localized diffusely ( Supplementary Figures 8d and e ).
EBF1-PDGFRB homodimerizes, is autophosphorylated and is stable relative to PDGFRB Normal PDGFRB signaling requires ligand-induced dimerization at the plasma membrane. 27 To determine whether EBF1-PDGFRB multimerizes, we performed co-immunoprecipitation followed by immunoblotting of Ebf1 −/− progenitors cotransduced with FLAGand MYC-tagged EBF1-PDGFRB. Pull down of FLAG-tagged EBF1-PDGFRB co-immunoprecipitated MYC-tagged EBF1-PDGFRB, and vice versa, confirming EBF1-PDGFRB multimerization (Figure 3a) . Additionally, HA-tagged TNIP1ex14-PDGFRB co-immunoprecipitated His 6 -tagged TNIP1ex14-PDGFRB ( Supplementary Figure 6d ) establishing that cytoplasmic self-association is common among PDGFRB fusion proteins. Importantly, confocal imaging revealed that coexpression of GFP-tagged EBF1-PDGFRB together with mCFP-tagged EBF1 did not alter the cytoplasmic or nuclear localization of either protein, respectively, in B-cell progenitors ( Figure 3b ). This suggests that unlike sequestration of WT IKAROS to the cytoplasm by IK6, EBF1 and EBF1-PDGFRB are sequestered to different subcellular compartments. This in turn effectively prevents the assembly of heterodimers (EBF1+EBF1-PDGFRB) in cells. It also explains our inability to detect heterodimers using coimmunoprecipitation (data not shown). Thus, loss of EBF1 function results from its fusion to PDGFRB and not to dominant-negative effects of EBF1-PDGFRB on EBF1.
Next, we determined whether EBF1-PDGFRB is capable of autophosphorylation. After transducing Ebf1 −/− cells with FLAGtagged versions of EBF1-PDGFRB or EBF1-PDGFRB(K634R), we performed IP followed by immunoblotting with panphosphotyrosine antibodies. EBF1-PDGFRB was strongly phosphorylated, which was inhibited by imatinib or the EBF1-PDGFRB (K634R) mutation (Figure 3c ).
Typically, PDGFRB is internalized and degraded upon ligandinduced dimerization. 22, 28, 29 Given PDGFRB's lack of surface expression on Ebf1 − / − cells and punctal localization compared with the diffuse cytoplasmic pattern of EBF1-PDGFRB ( Figures 2c  and d and Supplementary Figure 5c ), we wanted to determine whether PDGFRB was less stable than EBF1-PDBFRB. We incubated Ebf1 − / − cells expressing these proteins with the translation inhibitor cycloheximide for 0, 4, 8 or 12 h before immunoblotting ( Figure 3d ). As expected, PDGFRB levels were greatly reduced after only 4 h, whereas EBF1-PDGFRB, EBF1-PDGFRB(K634R) and EBF1-PDGFRB(ΔTM) levels were unchanged up to 8 h and decreased only slightly at 12 h. Additionally, removal of EBF1 greatly reduced the stability of the PDGFRB(528-1106) fragment.
EBF1-PDGFRB promotes cytokine-independent and clonogenic growth of B-cell progenitors, which is targetable by TKI therapy
To determine whether EBF1-PDGFRB is sufficient to transform IL-7dependent Ebf1 −/− progenitors, we transduced these cells with various constructs and expanded infected cells over 16 days with SCF and FLT3L, but without IL-7. As expected, only EBF1-PDGFRBpositive cells proliferated (Figure 4a ). 3 Removal of SCF and/or FLT3L revealed significant contributions of these cytokines to the growth rates of EBF1-PDGFRB-positive cells ( Supplementary  Figure 9 ). Unexpectedly, both EBF1-PDGFRB(ΔTM)-and PDGFRB (528-1106)-positive cells failed to proliferate in the absence of IL-7 at any time despite having a functional PDGFRB kinase domain (Figure 4a ). Our results establish that, along with a functioning TK domain, fusion of EBF1 to PDGFRB(528-1106) and TM-mediated cytoplasmic localization of EBF1-PDGFRB are also necessary to achieve EBF1-PDGFRB-mediated cytokine independence.
We then confirmed that exogenous cytokines are not required for proliferation of IL-3-dependent Ba/F3 pro-B cells or IL-7dependent primary mouse Arf − / − pre-B cells expressing PDGFRB fusions to EBF1, TNIP1, ATF7IP or CD74 (Figures 4a and b) . In patients harboring rearrangements of PDGFRB, these lesions frequently co-occur with IKZF1 alterations and CDKN2A (Arf -/-) deletions; therefore, we coexpressed the dominant-negative IKZF1 isoform (IK6) with each of the fusions in Arf −/− pre-B cells, which provide a genetically faithful model of human B-ALL. Coexpression of IK6 did not significantly increase the proliferation rates of ATF7IP-PDGFRB or EBF1-PDGFRB-expressing pre-B cells. However, IK6 coexpression was required for the growth of TNIP1ex14-PDGFRB-positive pre-B cells; Arf − / − cells expressing TNIP1ex14-PDGFRB without IK6 do not survive in the absence of IL-7, and, therefore, were not included in the growth assay (Figure 4b) .
Mechanistically, PDGFRB fusions to EBF1, TNIP1 or ATF7IP activate the STAT5 pathway to bypass the cytokine dependence in both Ba/F3 and Arf −/− cells (Figure 4c ). 3, 8 This activation can be reversed by treatment with the TKI dasatinib. Likewise, in Ebf1 − / − cells lacking IL-7, EBF1-PDGFRB expression activated STAT5 signaling, which was blocked by imatinib or mutant EBF1-PDGFRB(K634R) kinase inhibition ( Supplementary Figure 10) . Surprisingly, cells expressing EBF1-PDGFRB(ΔTM), which failed to expand in the absence of IL-7, still activated STAT5 but to a lesser extent than full-length EBF1-PDGFRB (Figure 4a and Supplementary Figure 10 ). Next, we performed cytotoxicity assays in vitro to assess the relative sensitivities of fusion proteins to the commonly used TKI dasatinib, and also to the class III TK inhibitors crenolanib and dovitinib. [30] [31] [32] Crenolanib binds the active confirmation of PDGFRA and has been used for the treatment of imatinib-resistant gastrointestinal stromal tumors, as has the multikinase inhibitor dovitinib. (Figure 4d ). Each of the three TKI's potently inhibited proliferation of cells expressing the PDGFRB fusion proteins.
We then expressed EBF1-PDGFRB, TNIP1ex14-PDGFRB and empty vector in C57Bl/6 WT and Arf −/− lineage-negative bone marrow hematopoietic progenitors and assessed colony-forming potential over serial replatings in vitro as a surrogate measure of self-renewal. All fusions failed at serial replating under myeloid conditions (IL-3, IL-6, SCF, granulocyte-macrophage colony-stimulating factor; data not shown), but induced serial replating under lymphoid conditions (IL-7, SCF, FLT3L; Figure 5a ). Morphological (Figure 5b ) and flow cytometric analyses (Figure 5c ) of colonyforming cells harvested after rounds 3-6 of replating revealed a lymphoid phenotype. TNIP1ex14-PDGFRB expression required concomitant loss of Arf to promote serial replating for B progenitor lymphoid colonies. In contrast, EBF1-PDGFRB potently supported serial B progenitor colony replating in a WT background with enhanced replating in Arf-null cells, supporting the notion that concomitant activation of kinase signaling and perturbation of lymphoid maturation (by inhibition of EBF1 by EBF1-PDGFRB, or bypassing kinase induced senescence by inactivation of ARF in the case of TNIP1ex14-PDGFRB) is required for lymphoid transformation, proliferation and self-renewal. EBF1-PDGFRB is leukemogenic, synergizes with IK6 and is antagonized by EBF1 Because both IKZF1 alterations and CDKN2A (Arf) deletions are frequently observed in Ph-like cases harboring PDGFRB fusions, we comodeled EBF1-PDGFRB with either empty vector or the dominant-negative isoform of IKAROS (IK6) in primary Arf − / − pre-B cells to determine oncogenicity in vivo. In the absence of an oncogenic driver Arf −/− pre-B cells, without or with IK6 expression, are not leukemogenic. 33 We then transplanted 1x10 6 Arf −/− pre-B cells expressing EBF1-PDGFRB together with empty vector or with IK6 by tail vein injection into sublethally irradiated WT recipients. EBF1-PDGFRB induced a fully penetrant leukemia with a median survival of 44 days (Figure 6a ). Disease onset and spleen weight were significantly increased with coexpression of IK6, resulting in a median survival of 37 days (Figures 6a and b) . Flow cytometric analysis of bone marrow and spleen from moribund mice revealed outgrowth of B progenitor leukemia (CD43 + CD19 + BP1 + IgM -), with reduced B220 expression in the IK6-coexpressing pre-B cells compared with their EBF1-PDGFRB-only expressing counterparts (Figure 6c ). Histological examination revealed that both EBF1-PDGFRB and EBF1-PDGFRB+IK6 leukemias were highly infiltrative across multiple tissues including the liver, lung and the central nervous system (Figure 6d) .
In leukemic patients, the high frequency of co-occurring lesions resulting in rearrangement or loss or EBF1 suggests that intact EBF1 may antagonize leukemogenesis. To test this, we infected Ebf1 − / − cells with EBF1-PDGFRB alone, or together with the 4-hydroxytamoxifen-dependent EBF1:estrogen receptor fusion, which allows for intracellular EBF1 titration in vitro. 24 We then sorted positive cells and expanded them in the absence of IL-7 across increasing dosages of 4-hydroxytamoxifen (increasing EBF1 levels) while maintaining constant EBF1-PDGFRB levels ( Supplementary Figures 11a and b) . Increasing the dosage of active EBF1 significantly reduced the ability of EBF1-PDGFRB to 
DISCUSSION
In this study, we defined novel mechanisms of EBF1-PDGFRBdependent leukemogenesis beyond dysregulated tyrosine kinase activity. Furthermore, we describe the first genetically faithful mouse model of Ph-like B-ALL, which confirms that EBF1-PDGFRB is sufficient to drive leukemogenesis in vivo. Additionally, EBF1-PDGFRB synergizes with the dominant-negative form of IKAROS, IK6.
Mechanistically, we observed dual contributions of cytoplasmic mislocalization of EBF1-PDGFRB, which not only promotes constitutive TK signaling via STAT5 activation but also prevents EBF1 from localizing within nuclei, activating B-cell-specific genes, and promoting B-lymphoid development (Figure 7) . Surprisingly, removal of the TM domain resulted in nuclear relocalization of EBF1-PDGFRB and partial restoration of EBF1 function. Removal of the TM domain also restored IL-7 dependence to B-cell progenitors expressing EBF1-PDGFRB, despite the presence of a functional TK domain. Interestingly, the EBF1 portion of EBF1-PDGFRB was not only required for IL-7 independence but also appeared to protect the oncoprotein from TM-dependent cytoplasmic degradation as EBF1-PDGFRB was the only TMcontaining construct that did not form cytoplasmic puncti ( Supplementary Figure 12) .
We conclude that the PDGFRB TM domain facilitates both nuclear export and interactions with other cytosolic proteins, which in turn promote TK activity and transformation by EBF1-PDGFRB. Mislocalization by the TM/NES is likely a shared property of other PDGFRB-containing fusion proteins (for example, ETV6-PDGFRB), which generally include this motif. 34 Subcellular mislocalization and enhanced protein stability also contribute to leukemogenesis by other TK fusion proteins. For example, transforming activities of the NUP214-ABL1 fusion is dependent on its association with nuclear pore complexes. 35 The mechanism that enhances stability of EBF1-PDGFRB is unknown, but it may be similar to the attenuation of proteosomal degradation reported for ETV6-PDGFRB, FIP1L1-PDGFRA and ZMYM2(ZNF198)-FGFR1. 36, 37 The loss of EBF1 function in EBF1-PDGFRB is likely a key determinant of perturbed lymphoid maturation in B-ALL. This may, in part, account for the notably poor outcome of human EBF-PDGFRB-positive B-ALL. 38 Similar to the loss of IKZF1 due to deletion or dominant-negative mutations, deletions of EBF1 genes or inhibition of EBF1 function in EBF1-PDGFRB impair B-cell maturation and are associated with poor outcomes. 39 In this regard, it is notable that restoration of EBF1 function in EBF1-PDGFRB, or enforced expression of EBF1, activated EBF1 target genes and blocked EBF1-PDGFRB-driven cell proliferation. These observations indicate that reestablishment of EBF1 function in EBF1-PDGFRB-positive B-ALL, that is, using inhibitors of the TM/NES of PDGFRB, 40 may provide an additional strategy for treating a subset of TKIrefractory leukemias.
Our studies highlight the importance of lineage maturation in preventing leukemogenesis. In B-ALL, the B-cell-specific transcriptional network is perturbed, and genomic profiling studies have revealed that factors involved in B-lymphoid specification, including IKZF1, PAX5 and EBF1 are commonly lost via mutation or deletion in 460% of patients, with a higher percentage in Ph + and Ph-like cases. [41] [42] These alterations are associated with transcriptional dedifferentiation and poor outcomes. Loss of normal EBF1 function is important for leukemogenesis by EBF1-PDGFRB, because intact EBF1 antagonizes functions of the fusion protein. We propose that EBF1-PDGFRB drives significant features of Ph-like B-ALL by itself, but is more potent in cells that have impaired homeostatic functions because of the loss of additional genes including the second allele of EBF1 itself, IKZF1 or by FLT3 gene duplications. 3, 39 Synergy between loss of these alterations and EBF1-PDGFRB has not been characterized at the molecular level; however, the loss of EBF1 and IKZF1 (for example, IK6) together likely perturbs regulation of common genes and pathways. 43 For example, alterations of IKZF1 results in arrested differentiation, acquisition of a hematopoietic stem cell-like phenotype and confers resistance to TKI therapy in models of BCR-ABL1-positive ALL. 44 Lesions in IKZF1 also activate expression of integrins and integrin signaling pathways. 43, 45 Taken together, effects of the loss of IKZF1 compound the loss of EBF1. In summary, our data confirm that loss of the tumor suppressor functions of EBF1, together with proliferative advantages provided by the TK function of PDGFRB, constitute a potent driver of leukemogenesis in B-ALL. 
EBF1-PDGFRB
